利福平治疗携带CYP24A1功能缺失变异患者的长期疗效与安全性
本文报告一名23岁男性婴儿高钙血症1型(HCINF1)患者,伴中度高钙血症(12.9 mg/dL)、症状性肾结石、肾钙质沉着和肾功能受损(eGFR 60 mL/min/1.73 m2),接受利福平治疗共24个月。2个月内血钙恢复正常(9.6 mg/dL)、肾功能改善(eGFR 92 mL/min/1.73 m2)且治疗期间稳定;15个月后因乏力暂时停药,3个月后将给药时间从早晨改为晚间,乏力缓解。随访结束时肾结石消失、肾钙质沉着稳定。作者认为利福平可能是HCINF1患者稳定降低钙水平的有效选择,安全性良好。
要点
- 23岁男性HCINF1患者接受利福平治疗24个月,2个月内血钙从12.9 mg/dL降至9.6 mg/dL并维持稳定。
- 治疗2个月内eGFR从60升至92 mL/min/1.73 m2,治疗期间保持稳定。
- 15个月时因乏力暂时停药,改为晚间给药后乏力缓解,随访末肾结石消失、肾钙质沉着稳定。
核心结论
- 利福平可能为HCINF1患者提供稳定降低钙水平的有效选择,且安全性良好。
研究设计与样本
- 单例病例报告:一名23岁男性HCINF1患者,接受利福平治疗总时长24个月,随访期间评估临床、生化及影像学特征,并每次随访评估肾、肝和肾上腺功能。
主要发现
- 治疗2个月内血钙从12.9 mg/dL降至9.6 mg/dL(恢复正常),eGFR从60 mL/min/1.73 m2升至92 mL/min/1.73 m2,治疗期间稳定。
- 治疗15个月后因乏力暂时停用利福平,乏力与肾上腺功能受损无关;3个月后将给药时间从早晨改为晚间,乏力缓解。
- 随访结束时肾结石消失,肾钙质沉着保持稳定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pharmacological therapy may be useful in the treatment of moderate to severe hypercalcemia in patients with infantile hypercalcemia-1 (HCINF1) due to pathogenic variants in the cytochrome P450 24 subfamily A member 1 (CYP24A1). Rifampin is an antituberculosis drug that is a potent inducer of cytochrome P450 3 subfamily A member 4, which is involved in an alternative catabolic pathway of vitamin D. The efficacy of rifampin in improving hypercalcemia was previously reported, but many questions remain on the long-term efficacy and safety. The aim of the study is to test the long-term efficacy and safety of rifampin in a patient with HCINF1. METHODS: We report clinical, biochemical, and imaging features of a 23-year-old man affected by HCINF1 with moderate hypercalcemia (12.9 mg/dL), symptomatic nephrolithiasis, nephrocalcinosis, and impaired kidney function [estimated glomerular filtration rate (eGFR) 60 mL/min/1.73 m2] treated with rifampin for an overall period of 24 months. Kidney, liver, and adrenal function were evaluated at every follow-up visit. RESULTS: In 2 months, rifampin induced a normalization of serum calcium (9.6 mg/dL) associated with an improvement of kidney function (eGFR 92 mL/min/1.73 m2) stable during the treatment. After 15 months, rifampin was temporally withdrawn because of asthenia, unrelated to impairment of adrenal function. After 3 months, the timing of drug administration was shifted from the morning to the evening, obtaining the remission of asthenia. At the end of follow-up, the nephrolithiasis disappeared and the nephrocalcinosis was stable. CONCLUSIONS: Rifampin could represent an effective choice to induce a stable reduction of calcium levels in patients with HCINF1, with a good safety profile.
引用
- Brancatella A, Cappellani D, Kaufmann M, et al. Long-term Efficacy and Safety of Rifampin in the Treatment of a Patient Carrying a CYP24A1 Loss-of-Function Variant. J Clin Endocrinol Metab. 2022. PMID: 35569070. doi:10.1210/clinem/dgac315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。